{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05829239",
            "orgStudyIdInfo": {
                "id": "202304058"
            },
            "organization": {
                "fullName": "Washington University School of Medicine",
                "class": "OTHER"
            },
            "briefTitle": "ADI-PEG20, Obesity and Prediabetes",
            "officialTitle": "A Randomized Trial Using ADI-PEG20 to Improve Insulin- and Energy Homeostasis in Adolescents With Obesity",
            "therapeuticArea": [
                "Endocrinology"
            ],
            "study": "adi-obesity-and-prediabetes"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-11-11",
            "studyFirstSubmitQcDate": "2023-04-24",
            "studyFirstPostDateStruct": {
                "date": "2023-04-25",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-24",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-25",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Washington University School of Medicine",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Children's Discovery Institute",
                    "class": "OTHER"
                },
                {
                    "name": "Polaris Pharmaceuticals, Inc.",
                    "class": "UNKNOWN"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Th purpose of this study is to determine whether ADI-PEG20 (PEGylated arginine deiminase), an arginine catabolizing enzyme preparation, improves insulin sensitivity, mitochondrial respiration, and energy utilization in adolescents with prediabetes.",
            "detailedDescription": "Obesity, insulin resistance, and their complications are major causes of morbidity and mortality in children, adolescents, and adults. Although caloric restriction is an effective treatment, intensive lifestyle changes are rarely durable. The investigators and others have shown that: (i.) fasting incites arginine catabolism, and forced arginine catabolism recapitulates several therapeutic effects of fasting, (ii.) exogenous, forced arginine catabolism improves metabolic health, and (iii.) ADI-PEG20 (PEGylated arginine deiminase) is an arginine catabolizing enzyme preparation that improves insulin sensitivity, mitochondrial respiration, and energy utilization in obese mice. The study will determine whether ADI-PEG20 also exerts beneficial effects on metabolic healthy in people. The investigators will perform a 12-week, randomized, double-blind, placebo-controlled trial in boys and girls with pre-diabetes to evaluate the efficacy of ADI-PEG20 treatment on: 1) body composition; 2) resting energy expenditure; 3) multi-organ insulin sensitivity; 3) \u03b2-cell function; and 4) muscle mitochondrial function."
        },
        "conditionsModule": {
            "conditions": [
                "Obesity",
                "PreDiabetes"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Single-center, randomized, double-blind, placebo-controlled study",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 48,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "ADI-PEG20",
                    "type": "EXPERIMENTAL",
                    "description": "ADI-PEG20 (ADI-PEG20 is arginine deiminase (ADI) conjugated to polyethylene glycol (PEG) of 20,000 molecular weight) will be weekly intramuscularly at a dose of 18 mg/m2 body surface area/week for 8-week.",
                    "interventionNames": [
                        "Biological: ADI-PEG20"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Will be weekly intramuscularly for 8-week",
                    "interventionNames": [
                        "Other: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "ADI-PEG20",
                    "description": "Intramuscular injection weekly for 8 weeks",
                    "armGroupLabels": [
                        "ADI-PEG20"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Placebo",
                    "description": "Intramuscular injection weekly for 8 weeks",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in insulin sensitivity",
                    "description": "Insulin sensitivity will be assessed by using the hyperinsulinemic-euglycemic clamp procedure",
                    "timeFrame": "Baseline and 8 weeks of ADI-PEG20 or placebo"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in oral glucose tolerance",
                    "description": "Oral glucose tolerance will be assessed by measuring plasma glucose concentrations before and after ingesting 75 grams glucose",
                    "timeFrame": "Baseline and 4 weeks of ADI-PEG20 or placebo"
                },
                {
                    "measure": "Change in oral glucose tolerance",
                    "description": "Oral glucose tolerance will be assessed by measuring plasma glucose concentrations before and after ingesting 75 grams glucose",
                    "timeFrame": "Baseline and 8 weeks of ADI-PEG20 or placebo"
                },
                {
                    "measure": "Change in \u03b2-cell function",
                    "description": "\u03b2-cell function will be assessed from a modified oral glucose tolerance test",
                    "timeFrame": "Baseline and 4 weeks of ADI-PEG20 or placebo"
                },
                {
                    "measure": "Change in \u03b2-cell function",
                    "description": "\u03b2-cell function will be assessed from a modified oral glucose tolerance test",
                    "timeFrame": "Baseline and 8 weeks of ADI-PEG20 or placebo"
                },
                {
                    "measure": "Change in resting energy expenditure",
                    "description": "Resting energy expenditure (in kcal/min) will be assessed by using indirect calorimetry",
                    "timeFrame": "Baseline and 8 weeks of ADI-PEG20 or placebo"
                },
                {
                    "measure": "Change in muscle mitochondrial respiration",
                    "description": "Muscle mitochondrial respiration (in pmol O2/mg tissue) will be assessed by using high resolution respirometry, conducted on permeabilized muscle fibers obtained by muscle biopsy.",
                    "timeFrame": "Baseline and 8 weeks of ADI-PEG20 or placebo"
                },
                {
                    "measure": "Change in intrahepatic triglyceride content",
                    "description": "Intrahepatic triglyceride content will be assessed by magnetic resonance imagining (MRI)",
                    "timeFrame": "Baseline and 8 weeks of ADI-PEG20 or placebo"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Change in the transcriptome in muscle",
                    "description": "The transcriptome will be evaluated by using RNA sequencing techniques",
                    "timeFrame": "Baseline and 8 weeks of ADI-PEG20 or placebo"
                },
                {
                    "measure": "Change in the transcriptome in adipose tissue",
                    "description": "The transcriptome will be evaluated by using RNA sequencing techniques",
                    "timeFrame": "Baseline and 8 weeks of ADI-PEG20 or placebo"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* age: \u226518 and \u226422 years;\n* BMI 25.0 - 44.9 kg/m2;\n* Prediabetes, defined as fasting plasma glucose of \u2265100 mg/dL, or HbA1C \u22655.7%, or HOMA-IR \u22652.5.\n\nExclusion Criteria:\n\n* HbA1C \u22656.5%;\n* Intolerance or allergies to ingredients in ADI-PEG20 or placebo;\n* Taking dietary supplements or medications known to affect our study outcomes;\n* Evidence of significant organ system dysfunction or diseases,\n* Metallic implants, which would preclude MRI",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "22 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Nikki Plassmeyer, MA, RDN, LD",
                    "role": "CONTACT",
                    "phone": "314-362-0590",
                    "email": "nikkip@wustl.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Samuel Klein, MD",
                    "affiliation": "Washington University School of Medicine",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Washington University School of Medicine",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Nikki Plassmeyer, MA, RDN, LD",
                            "role": "CONTACT",
                            "phone": "314-362-0590",
                            "email": "nikkip@wustl.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009765",
                    "term": "Obesity"
                },
                {
                    "id": "D000011236",
                    "term": "Prediabetic State"
                },
                {
                    "id": "D000018149",
                    "term": "Glucose Intolerance"
                }
            ],
            "ancestors": [
                {
                    "id": "D000050177",
                    "term": "Overweight"
                },
                {
                    "id": "D000044343",
                    "term": "Overnutrition"
                },
                {
                    "id": "D000009748",
                    "term": "Nutrition Disorders"
                },
                {
                    "id": "D000001835",
                    "term": "Body Weight"
                },
                {
                    "id": "D000003920",
                    "term": "Diabetes Mellitus"
                },
                {
                    "id": "D000044882",
                    "term": "Glucose Metabolism Disorders"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                },
                {
                    "id": "D000006943",
                    "term": "Hyperglycemia"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12701",
                    "name": "Obesity",
                    "asFound": "Obesity",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14117",
                    "name": "Prediabetic State",
                    "asFound": "Prediabetes",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20295",
                    "name": "Glucose Intolerance",
                    "asFound": "Prediabetes",
                    "relevance": "HIGH"
                },
                {
                    "id": "M26186",
                    "name": "Overweight",
                    "relevance": "LOW"
                },
                {
                    "id": "M25307",
                    "name": "Overnutrition",
                    "relevance": "LOW"
                },
                {
                    "id": "M12684",
                    "name": "Nutrition Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5114",
                    "name": "Body Weight",
                    "relevance": "LOW"
                },
                {
                    "id": "M7115",
                    "name": "Diabetes Mellitus",
                    "relevance": "LOW"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M25403",
                    "name": "Glucose Metabolism Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9994",
                    "name": "Hyperglycemia",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M10365",
                    "name": "Insulin",
                    "relevance": "LOW"
                },
                {
                    "id": "M173166",
                    "name": "Insulin, Globin Zinc",
                    "relevance": "LOW"
                },
                {
                    "id": "T1",
                    "name": "Arginine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hypo",
                    "name": "Hypoglycemic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "AA",
                    "name": "Amino Acids"
                }
            ]
        }
    },
    "hasResults": false
}